AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 211 min read$BOLT

Yonehiro Grant sold $44K of BOLT

Yonehiro Grant (Chief Operating Officer) sold 13,176 shares of Bolt Biotherapeutics, Inc. (BOLT) at an average of $3.32 ($3.24–$3.77) across 3 trades over 2026-09-16 to 2026-09-18.

Original reporting
SEC EDGAR · Yonehiro Grant
Published Sep 21, 2026, 10:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 21, 2026, 10:14 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$BOLT
Neutral
high confidence
Mentioned
$BOLT
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$BOLTNeutralLow
01

Why it matters

The sale is modest and unlikely to affect market perception significantly.

02

Market read

Routine insider sale with limited trading relevance.

03

What to watch

Potential upcoming corporate actions not disclosed.

Relevance 3/10Novelty 4/10Timing: filed Sep 21 2026

Background

Form 4 filing reports insider transactions to the SEC.

Company-level read

Ticker impact

$BOLTNeutralHigh confidence
Context

COO Yonehiro Grant sold 13,176 shares of Bolt Biotherapeutics for $43.8K in a Form 4 filing.

Expected impact

Limited short-term pressure; unlikely to move price materially.

Evidence & confidence

The transaction size ($44K) is small relative to market cap; market may view it as routine.

Market effects

Sector

No significant impact on biotech sector.

Regional

None.

Global

Minimal.

Counterpoint

What could challenge this read

Sale could be unrelated personal liquidity need; not a bearish signal.

Key entities

  • Company
    Bolt Biotherapeutics, Inc.

    Biotech firm listed on Nasdaq (BOLT).

  • Person
    Yonehiro Grant

    Chief Operating Officer of Bolt Biotherapeutics.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

BOLT insider trading history →

Related articles

OCT 23
$BOLTHigh

Bolt Biotherapeutics, Inc. (BOLT): Completion of Acquisition or Disposition of Assets

Bolt Biotherapeutics, Inc. (BOLT) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. Exhibit 99.1 Bolt Biotherapeutics Announces Acquisition of Prana Therapies and $120 Million Concurrent Private Placement to Advance PRA-216 in Multiple High-Value Inflammatory Indications • Transactions position the company to advance Prana’s pipeline of next-generation, half-lif

SEC EDGAR 8-K2 min
OCT 23
$BOLTMed

Bolt Biotherapeutics Announces Acquisition Of Prana Therapies, $120 Mln Concurrent Private Placement

Bolt Biotherapeutics (BOLT) acquired Prana Therapies via a stock-for-stock deal, exchanging shares for Prana's equity. Bolt also secured $120 million in a private placement, issuing Series D preferred stock and warrants. The funds will support operations into 2028. Prana's co-founder, Sheila Gujrathi, joined Bolt's board as chief strategy officer. BOLT shares closed at $4.19 on Nasdaq.

rttnews.com1 min
OCT 23
$BOLTHighAI 8/10

Bolt Biotherapeutics acquires Prana in reverse merger deal

Bolt Biotherapeutics (BOLT) acquired Prana Therapies in a reverse merger, raising $120M with potential for $60M more. Post-merger, Prana shareholders own 51.7% of Bolt. The combined company will advance Prana's INSPIRE platform, with Phase 2 data expected in Q2 2027. Sheila Gujrathi, Prana's co-founder, joins Bolt's board.

investing.com2 min
OCT 23
$BOLTMedAI 8/10

A $120 million financing is expected to fund Bolt's operations into 2028

Bolt Biotherapeutics (BOLT) acquired Prana Therapies, securing $120M in financing, with up to $60M more possible. The deal advances Prana's pipeline, including PRA-216, a bispecific antibody in Phase 2 trials for asthma, COPD, and atopic dermatitis. Data from all trials is expected in Q2 2027. Dr. Sheila Gujrathi, Prana's co-founder, joins Bolt's executive team. The financing is expected to fund operations into 2028.

stocktitan.net2 min